SB-505124 Is a Selective Inhibitor of Transforming Growth Factor-β Type I Receptors ALK4, ALK5, and ALK7

Molecular Pharmacology

Volumn 65, Issue 3, 2004, Pages 744-752

  DaCosta Byfield, Stacey ^a   Major, Christopher ^a   Laping, Nicholas J ^b   Roberts, Anita B ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 (1,3 BENZODIOXOL 5 YL) 5 (2 PYRIDINYL) 1H IMIDAZOL 2 YL]BENZAMIDE; ACTIVIN RECEPTOR; ACTIVIN RECEPTOR LIKE KINASE 4; ACTIVIN RECEPTOR LIKE KINASE 7; IMIDAZOLE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE; SB 505124; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL STRAIN COS1; CELL STRAIN HEPG2; CELL VIABILITY; COMPETITIVE INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG SELECTIVITY; EPITHELIZATION; FIBROSIS; GENETIC TRANSFECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REPORTER GENE; SCAR FORMATION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ACTIVIN RECEPTORS, TYPE I; ACTIVINS; ANIMALS; BENZAMIDES; CELL DEATH; COS CELLS; DIOXOLES; DNA-BINDING PROTEINS; DRUG INTERACTIONS; GENES, REPORTER; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASES; PROTEINS; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SMAD PROTEINS; TRANS-ACTIVATORS; TRANSFORMING GROWTH FACTOR BETA; TUMOR CELLS, CULTURED;

EID: 1342265719     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.65.3.744     Document Type: Article

References (36)

1. Ashcroft GS, Yang X, Glick AB, Weinstein M, Letterio JL, Mizel DE, Anzano M, Greenwell-Wild T, Wahl SM, Deng C, et al. (1999) Mice lacking Smad3 show accelerated wound healing and an impaired local inflammatory response. Nat Cell Biol 1:260-266.
2. Bettinger DA, Yager DR, Diegelmann RF, and Cohen IK (1996) The effect of TGF-beta on keloid fibroblast proliferation and collagen synthesis. Plast Reconstr Surg 98:827-833.
3. Border WA and Noble NA (1994) Transforming growth factor beta in tissue fibrosis. N Engl J Med 331:1286-1292.
4. Callahan JF, Burgess JL, Fornwald JA, Gaster LM, Harling JD, Harrington FP, Heer J, Kwon C, Lehr R, Mathur A, et al. (2002) Identification of novel inhibitors of the transforming growth factor beta1 (TGF-beta1) type 1 receptor (ALK5). J Med Chem 45:999-1001.
5. Chen X, Rubock MJ, and Whitman M (1996) A transcriptional partner for MAD proteins in TGF-beta signalling. Nature (Lond) 383:691-696.
6. Chen X, Weisberg E, Fridmacher V, Watanabe M, Naco G, and Whitman M (1997) Smad4 and FAST-1 in the assembly of activin-responsive factor. Nature (Lond) 389:85-89.
7. de Caestecker MP, Parks WT, Frank CJ, Castagnino P, Bottaro DP, Roberts AB, and Lechleider RJ (1998) Smad2 transduces common signals from receptor serine-threonine and tyrosine kinases. Genes Dev 12:1587-1592.
8. de Caestecker MP, Piek E, and Roberts AB (2000) Role of transforming growth factor-beta signaling in cancer. J Natl Cancer Inst 92:1388-1402.
9. Dennler S, Itoh S, Vivien D, ten Dijke P, Huet S, and Gauthier JM (1998) Direct binding of Smad3 and Smad4 to critical TGF beta-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. EMBO (Eur Mol Biol Organ) J 17:3091-3100.
10. Derynck R, Akhurst RJ, and Balmain A (2001) TGF-beta signaling in tumor suppression and cancer progression. Nat Genet 29:117-129.
11. Flanders KC, Sullivan CD, Fujii M, Sowers A, Anzano MA, Arabshahi A, Major C, Deng C, Russo A, Mitchell JB, et al. (2002) Mice lacking Smad3 are protected against cutaneous injury induced by ionizing radiation. Am J Pathol 160:1057-1068.
12. Goumans MJ, Valdimarsdottir G, Itoh S, Rosendahl A, Sideras P, and ten Dijke P (2002) Balancing the activation state of the endothelium via two distinct TGF-beta type I receptors. EMBO (Eur Mol Biol Organ) J 21:1743-1753.
13. Hakenjos L, Bamberg M, and Rodemann HP (2000) TGF-beta1-mediated alterations of rat lung fibroblast differentiation resulting in the radiation-induced fibrotic phenotype. Int J Radiat Biol 76:503-509.
14. Heldin CH, Miyazono K, and ten Dijke P (1997) TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature (Lond) 390:465-471.
15. Hsing AY, Kadomatsu K, Bonham MJ, and Danielpour D (1996) Regulation of apoptosis induced by transforming growth factor-befa1 in nontumorigenic rat prostatic epithelial cell lines. Cancer Res 56:5146-5149.
16. Inman GJ, Nicolas FJ, Callahan JF, Harling JD, Gaster LM, Reith AD, Laping NJ, and Hill CS (2002a) SB-431542 is a potent and specific inhibitor of transforming growth factor-β superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5 and ALK7. Mol Pharmacol 62:65-74.
17. Inman GJ, Nicolas FJ, and Hill CS (2002b) Nucleocytoplasmic shuttling of Smads 2, 3 and 4 permits sensing of TGF-beta receptor activity. Mol Cell 10:283-294.
18. Jornvall H, Blokzijl A, ten Dijke P, and Ibanez CF (2001) The orphan receptor serine/threonine kinase ALK7 signals arrest of proliferation and morphological differentiation in a neuronal cell line. J Biol Chem 276:5140-5146.
19. Kim BC, Mamura M, Choi KS, Calabretta B, and Kim SJ (2002) Transforming growth factor beta 1 induces apoptosis through cleavage of BAD in a Smad3-dependent mechanism in FaO hepatoma cells. Mol Cell Biol 22:1369-1378.
20. Korchynskyi O and ten Dijke P (2002) Identification and functional characterization of distinct critically important bone morphogenetic protein-specific response elements in the Id1 promoter. J Biol Chem 277:4883-4891.
21. Laping NJ, Grygielko E, Mathur A, Butter S, Bomberger J, Tweed C, Martin W, Fornwald J, Lehr R, Harling J, et al. (2002) Inhibition of transforming growth factor (TGF)-β1-induced extracellular matrix with a novel inhibitor of the TGF-β type I receptor kinase activity: SB-431542. Mol Pharmacol 62:58-64.
22. Larisch-Bloch S, Danielpour D, Roche NS, Lotan R, Hsing AY, Kerner H, Hajouj T, Lechleider RJ, and Roberts AB (2000) Selective loss of the transforming growth factor-beta apoptotic signaling pathway in mutant NRP-154 rat prostatic epithelial cells. Cell Growth Differ 11:1-10.
23. Liu F, Pouponnot C, and Massague J (1997) Dual role of the Smad4/DPC4 tumor suppressor in TGFbeta-inducible transcriptional complexes. Genes Dev 11:3157-3167.
24. Martin M, Lefaix J, and Delanian S (2000) TGF-beta1 and radiation fibrosis: a master switch and a specific therapeutic target? Int J Radiat Oncol Biol Phys 47:277-290.
25. Massague J (1998) TGF-beta signal transduction. Annu Rev Biochem 67:753-791.
26. Mulder KM (2000) Role of Ras and Mapks in TGFbeta signaling. Cytokine Growth Factor Rev 11:23-35.
27. Nakao A, Imamura T, Souchelnytskyi S, Kawabata M, Ishisaki A, Oeda E, Tamaki K, Hanai J, Heldin CH, Miyazono K, et al. (1997) TGF-beta receptor-mediated signalling through Smad2, Smad3 and Smad4. EMBO (Eur Mol Biol Organ) J 16:5353-5362.
28. O'Kane S and Ferguson MW (1997) Transforming growth factor beta s and wound healing. Int J Biochem Cell Biol 29:63-78.
29. Oh SP, Seki T, Goss KA, Imamura T, Yi Y, Donahoe PK, Li L, Miyazono K, ten Dijke P, Kim S, et al. (2000) Activin receptor-like kinase 1 modulates transforming growth factor-beta 1 signaling in the regulation of angiogenesis. Proc Natl Acad Sci USA 97:2626-2631.
30. Park HJ, Kim BC, Kim SJ, and Choi KS (2002) Role of MAP kinases and their cross-talk in TGF-beta1-induced apoptosis in FaO rat hepatoma cell line. Hepatology 35:1360-1371.
31. Piek E and Roberts AB (2001) Suppressor and oncogenic roles of transforming growth factor-beta and its signaling pathways in tumorigenesis. Adv Cancer Res 83:1-54.
32. Reissmann E, Jornvall H, Blokzijl A, Andersson O, Chang C, Minchiotti G, Persico MG, Ibanez CF, and Brivanlou AH (2001) The orphan receptor ALK7 and the activin receptor ALK4 mediate signaling by nodal proteins during vertebrate development. Genes Dev 15:2010-2022.
33. Singer AJ and Clark RA (1999) Cutaneous wound healing. N Engl J Med 341:738-746.
34. Sporn MB and Roberts AB (1990) TGF-beta: problems and prospects. Cell Regul 1:875-882.
35. Wakefield LM and Roberts AB (2002) TGF-beta signaling: positive and negative effects on tumorigenesis. Curr Opin Genet Dev 12:22-29.
36. Watanabe R, Yamada Y, Ihara Y, Someya Y, Kubota A, Kagimoto S, Kuroe A, Iwakura T, Shen ZP, Inada A, et al. (1999) The MH1 domains of Smad2 and Smad3 are involved in the regulation of the ALK7 signals. Biochem Biophys Res Commun 254:707-712.